A Pilot Study of Pre-Operative, Single-Dose Ipilimumab, Nivolumab and Cryoablation in Early Stage/Resectable Breast Cancer
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Early breast cancer
- Focus Adverse reactions
- 07 Jun 2024 Status changed from active, no longer recruiting to completed.
- 03 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 03 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.